Study With Palonosetron Alone in Preventing Chemotherapy-induced Nausea and Vomiting in Untreated Patients With Aggressive Non Hodgkin's Lymphomas Who Underwent Moderately Emetogenic Chemotherapy

Exclusion Criteria

• •Highly emetogenic chemotherapy (containing cisplatin, mechlorethamine, streptozotocin, cyclophosphamide \>1500 mg/sqm; carmustine; dacarbazine; hexamethylmelamine; procarbazine), or single-agent chemotherapy with drugs having low/minimal emetogenic potential according to the Hesketh classification);
• •Diagnosis of Hodgkin's Disease or Leukemia;
• •Candidates to High-Dose Chemotherapy or Bone Marrow/Peripheral Blood Stem Cells Transplantation;
• •Chemotherapy schedules considering the administration of emetogenic drugs in more than two consecutive days;
• •Have received any investigational drugs within 30 days before study entry;
• •Have received any drug with potential anti-emetic efficacy (with the exception of specific corticosteroids foreseen in the chemotherapy combination) within 24 hours of treatment initiation);
• •Prior treatment with Palonosetron;
• •Have a seizure disorder requiring anticonvulsant medication unless clinically stable and free of seizure activity;
• •Experienced or ongoing vomiting or nausea from any organic etiology, in the screening phase;
• •Clinical evidence of current or impending bowel obstruction, peritonitis, infection, uremia, severe mucositis;
• •Clinically relevant electrolyte abnormalities;
• •Have a known hypersensitivity to 5HT3 receptor antagonists;
• •Radiotherapy within 30 days before chemotherapy administration, or scheduled to receive radiotherapy within two weeks after chemotherapy;
• •Female patients who are pregnant or breast feeding;
• •Inability to understand or cooperate with the study procedures.